Apellis Pharmaceuticals Inc (NASDAQ:APLS) gets upgraded to Overweight by JPMorgan Chase & Co.

ME Staff
-
0

Analyst Ratings For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

Today, Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock received an upgrade by JPMorgan Chase & Co. from Neutral to Overweight.

There are 7 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Apellis Pharmaceuticals Inc (NASDAQ:APLS) is Buy with a consensus target price of $43.2857 per share, a potential 65.72% upside.

Some recent analyst ratings include

  • 7/12/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) gets upgraded to Overweight by JPMorgan Chase & Co.
  • 7/9/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) has coverage initiated with a Outperform rating and $52.00 price target
  • 6/16/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) had its Buy rating reiterated by Cowen with a $40.00 price target
  • 5/8/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) had its Buy rating reiterated by Cantor Fitzgerald with a $52.00 price target
  • 3/28/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) has coverage initiated with a Outperform ➝ Outperform rating and $45.00 price target
  • 1/8/2019-Apellis Pharmaceuticals Inc (NASDAQ:APLS) has coverage initiated with a Buy rating and $40.00 price target
  • On 3/11/2019 Morningside Venture Investment, Major Shareholder, bought 441,176 with an average share price of $17.00 per share and the total transaction amounting to $7,499,992.00.
  • On 9/21/2018 Morningside Venture Investment, Major Shareholder, bought 81,323 with an average share price of $19.48 per share and the total transaction amounting to $1,584,172.04.
  • On 9/19/2018 Morningside Venture Investment, Major Shareholder, bought 140,000 with an average share price of $18.34 per share and the total transaction amounting to $2,567,600.00.
  • On 9/14/2018 David O Watson, General Counsel, sold 15,776 with an average share price of $18.78 per share and the total transaction amounting to $296,273.28.
  • On 5/24/2018 Lukas Scheibler, Insider, bought 2,935 with an average share price of $20.37 per share and the total transaction amounting to $59,785.95.
  • On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.

About Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. Read More…

Recent Trading Activity for Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals Inc closed the previous trading session at 26.12 −0.76 2.83% with 26.86 shares trading hands.